Prognostic Factors Associated with the Transition in Treatment Methods for Brain Metastases from Colorectal Cancer

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2023 May 19

PMID 37208499

Authors

Jun Imaizumi

Dai Shida

Narikazu Boku

Hiroshi Igaki

Jun Itami

Yasuji Miyakita

Yoshitaka Narita

Atsuo Takashima

Yukihide Kanemitsu

Affiliations

Soon will be listed here.

Abstract

Background: Treatment of brain metastases (BMs) from colorectal cancer (CRC) has transitioned with the expansion of indications for stereotactic radiotherapy. Our study aimed to assess changes in prognosis and prognostic factors associated with changes in treatment for BMs from CRC.

Methods: We retrospectively surveyed treatments for and outcomes of BMs from CRC in 208 patients treated during 1997-2018. Patients were divided into two groups according to time of BM diagnosis, i.e., 1997-2013 ("first period") and 2014-2018 ("second period"). We compared overall survival between the periods and assessed how the transition impacted prognostic factors affecting overall survival, including the following prognostic factors such as Karnofsky performance status (KPS), volume-related factors (BM number and diameter), and BM treatment modalities as covariates.

Results: Of the 208 patients, 147 were treated in the first period and 61 in the second period. Whole-brain radiotherapy use decreased from 67 to 39% in the second period, and stereotactic radiotherapy use increased from 30 to 62%. Median survival after BM diagnosis improved from 6.1 to 8.5 months (p = 0.0272). Multivariate analysis revealed KPS, control of primary tumor, stereotactic radiotherapy use, and chemotherapy history as independent prognostic factors during the entire observation period. Hazard ratios of KPS, primary tumor control, and stereotactic radiotherapy were higher in the second period, whereas prognostic impact of chemotherapy history before BM diagnosis was similar in both periods.

Conclusion: Overall survival of patients with BMs from CRC improved since 2014, which can be attributed to advances in chemotherapy and the more widespread use of stereotactic radiotherapy.

Citing Articles

Five-Fraction Radiosurgery Using a Biologically Equivalent Dose of a Single Fraction of 24 Gy for a 3-cm Parasagittal Para-Central Sulcus Brain Metastasis From Adenocarcinoma of the Cecum.

Ohtakara K, Kondo T, Obata Y, Fujii K, Suzuki K Cureus. 2023; 15(11):e48799.

PMID: 38098911 PMC: 10720925. DOI: 10.7759/cureus.48799.

References

Chang E, Wefel J, Hess K, Allen P, Lang F, Kornguth D . Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10(11):1037-44. DOI: 10.1016/S1470-2045(09)70263-3. View

Brown P, Jaeckle K, Ballman K, Farace E, Cerhan J, Anderson S . Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016; 316(4):401-409. PMC: 5313044. DOI: 10.1001/jama.2016.9839. View

Aprile G, Zanon E, Tuniz F, Iaiza E, De Pauli F, Pella N . Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J Cancer Res Clin Oncol. 2008; 135(3):451-7. DOI: 10.1007/s00432-008-0468-1. View

Schoeggl A, Kitz K, Reddy M, Zauner C . Stereotactic radiosurgery for brain metastases from colorectal cancer. Int J Colorectal Dis. 2002; 17(3):150-5. DOI: 10.1007/s00384-001-0362-7. View

Jung M, Ahn J, Chang J, Suh C, Hong S, Roh J . Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol. 2010; 101(1):49-55. DOI: 10.1007/s11060-010-0214-9. View

Sperduto P, Kased N, Roberge D, Xu Z, Shanley R, Luo X . Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011; 30(4):419-25. PMC: 3269967. DOI: 10.1200/JCO.2011.38.0527. View

Baek J, Kang M, Hong Y, Kim T, Kim D, Oh J . Characteristics and prognosis of patients with colorectal cancer-associated brain metastases in the era of modern systemic chemotherapy. J Neurooncol. 2011; 104(3):745-53. DOI: 10.1007/s11060-011-0539-z. View

Imaizumi J, Shida D, Narita Y, Miyakita Y, Tanabe T, Takashima A . Prognostic factors of brain metastases from colorectal cancer. BMC Cancer. 2019; 19(1):755. PMC: 6670227. DOI: 10.1186/s12885-019-5973-x. View

Kayama T, Sato S, Sakurada K, Mizusawa J, Nishikawa R, Narita Y . Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. J Clin Oncol. 2018; :JCO2018786186. DOI: 10.1200/JCO.2018.78.6186. View

10.

Walter S, Tiemeier H . Variable selection: current practice in epidemiological studies. Eur J Epidemiol. 2009; 24(12):733-6. PMC: 2791468. DOI: 10.1007/s10654-009-9411-2. View

11.

Brown P, Ballman K, Cerhan J, Anderson S, Carrero X, Whitton A . Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017; 18(8):1049-1060. PMC: 5568757. DOI: 10.1016/S1470-2045(17)30441-2. View

12.

Barnholtz-Sloan J, Sloan A, Davis F, Vigneau F, Lai P, Sawaya R . Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004; 22(14):2865-72. DOI: 10.1200/JCO.2004.12.149. View

13.

Sperduto P, Chao S, Sneed P, Luo X, Suh J, Roberge D . Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2009; 77(3):655-61. DOI: 10.1016/j.ijrobp.2009.08.025. View

14.

Narita Y, Sato S, Kayama T . Review of the diagnosis and treatment of brain metastases. Jpn J Clin Oncol. 2021; 52(1):3-7. DOI: 10.1093/jjco/hyab182. View

15.

Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R . Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26(12):2013-9. DOI: 10.1200/JCO.2007.14.9930. View

16.

Sun G, Shook T, Kay G . Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996; 49(8):907-16. DOI: 10.1016/0895-4356(96)00025-x. View

17.

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View

18.

Schouten L, Rutten J, Huveneers H, Twijnstra A . Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002; 94(10):2698-705. DOI: 10.1002/cncr.10541. View

19.

Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T . Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2019; 25(1):1-42. PMC: 6946738. DOI: 10.1007/s10147-019-01485-z. View

20.

Stillwell A, Ho Y, Veitch C . Systematic review of prognostic factors related to overall survival in patients with stage IV colorectal cancer and unresectable metastases. World J Surg. 2010; 35(3):684-92. DOI: 10.1007/s00268-010-0891-8. View